Jay R. Luly
President and CEO at Enanta Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Enanta Pharmaceuticals Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Enanta Pharmaceuticals Inc. March 11, 202699.2%
-
Enanta Pharmaceuticals Inc. March 2, 202394.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 12, 2026 | Enanta Pharmaceuticals Inc. | Grant or award | +4,800 | — | — |
| Feb 12, 2026 | Enanta Pharmaceuticals Inc. | Grant or award | +15,200 | — | — |
| Feb 12, 2026 | Enanta Pharmaceuticals Inc. | Shares withheld for tax | −6,155 | $14.25 | $87,709 |
| Dec 5, 2025 | Enanta Pharmaceuticals Inc. | Open-market sale | −4,743 | $14.23 | $67,493 |
| Dec 1, 2025 | Enanta Pharmaceuticals Inc. | Shares withheld for tax | −1,885 | $14.12 | $26,616 |
| Feb 12, 2025 | Enanta Pharmaceuticals Inc. | Grant or award | +25,500 | — | — |
| Feb 12, 2025 | Enanta Pharmaceuticals Inc. | Open-market purchase | +45,000 | $5.69 | $256,050 |
| Feb 12, 2025 | Enanta Pharmaceuticals Inc. | Shares withheld for tax | −7,484 | $5.59 | $41,836 |
| Dec 6, 2024 | Enanta Pharmaceuticals Inc. | Open-market sale | −5,142 | $8.06 | $41,445 |
| Dec 1, 2024 | Enanta Pharmaceuticals Inc. | Shares withheld for tax | −3,829 | $8.60 | $32,929 |
| Feb 12, 2024 | Enanta Pharmaceuticals Inc. | Grant or award | +5,400 | — | — |
| Feb 12, 2024 | Enanta Pharmaceuticals Inc. | Shares withheld for tax | −1,584 | $12.41 | $19,657 |
| Dec 5, 2023 | Enanta Pharmaceuticals Inc. | Open-market sale | −7,230 | $9.63 | $69,625 |
| Dec 1, 2023 | Enanta Pharmaceuticals Inc. | Shares withheld for tax | −5,787 | $9.49 | $54,919 |
| Mar 13, 2023 | Enanta Pharmaceuticals Inc. | Option exercise | +27,912 | $14.00 | $390,768 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.